ArticleJournal of neurodevelopmental disorders2011
Treatment effects of stimulant medication in young boys with fragile X syndrome.
Article in Journal of neurodevelopmental disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- State-of-the-art therapies for fragile X syndrome.Developmental medicine and child neurology · 2024Review
- Targeted Treatments for Fragile X Syndrome.Advances in neurobiology · 2023Article
- Attention/Deficit Hyperactivity Disorder in Adolescent and Young Adult Males With Fragile X Syndrome.American journal on intellectual and developmental disabilities · 2022Article
- New Therapeutic Options for Fragile X Syndrome.Current treatment options in neurology · 2019Review
- Change in the Behavioral Phenotype of Adolescents and Adults with FXS: Role of the Family Environment.Journal of autism and developmental disorders · 2016Article
- HPA axis function predicts development of working memory in boys with FXS.Brain and cognition · 2016Article
- The emergence and stability of attention deficit hyperactivity disorder in boys with fragile X syndrome.Journal of intellectual disability research : JIDR · 2016Article
- Overview: referrals for genetic evaluation from child psychiatrists.Child and adolescent psychiatry and mental health · 2016Article
- Cardiac autonomic regulation in autism and Fragile X syndrome: a review.Psychological bulletin · 2015Review
- Physiological arousal in autism and fragile X syndrome: group comparisons and links with pragmatic language.American journal on intellectual and developmental disabilities · 2013Article
- Attention deficit hyperactivity disorder in epileptic children.Journal of Korean medical science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and is caused by a CGG repeat expansion at Xq27.3 on the FMR1 gene. The majority of young boys with FXS display poor attention and hyperactivity that is disproportionate to their cognitive disability, and approximately 70% meet diagnostic criteria for attention-deficit/hyperactivity disorder. Psychopharmacology is employed with 82% of young males 5-17 years of age, with stimulant medication as the most common medication prescribed. This study evaluated the effects of stimulant medication on the academic performance, attention, motor activity, and psychophysiological arousal of boys with FXS, as well as the concordance of effects within individuals. Participants in this study included 12 boys with FXS who were treated with stimulants. Participants completed videotaped academic testing on two consecutive days and were randomly assigned to be off stimulants for 1 day and on stimulants the other day. On each day, multiple measures including academic performance, behavior regulation, and psychophysiological arousal were collected. Approximately 75% of participants performed better on attention and academic measures, and 70% showed improved physiological regulation while on stimulant medication. A high degree of concordance among measures was found. Lower intelligence quotient (IQ), but not age, correlated with greater improvements in in-seat behavior. IQ and age did not relate to on-task behaviors. The frequency and magnitude of response to stimulant medication in boys with FXS is higher than those reported for most children with non-specific intellectual disabilities and autism spectrum disorder.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.